Asylia Therapeutics, Inc. — Form D
Asylia Therapeutics, Inc. of HOUSTON, TX, a company, filed a Form D exempt-offering notice with the SEC on 2021-03-03. The offering totals $16.2M, of which $8.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-03-03
- Form: D
- Accession: 0001847837-21-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $16.2M
- Amount sold: $8.2M
- Remaining: $8.0M
- Investors: 1
- Date of first sale: 2021-02-16
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-391131
Issuer
- Name: Asylia Therapeutics, Inc.
- CIK: 0001847837
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 3139 W HOLCOMBE BLVD, HOUSTON, TX, 77025
- Phone: 617-921-9645
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Elan Ezickson | Director | Cambridge, MA |
| Jeno Gyuris | Director | Houston, TX |
| Joseph Kekst | Director | New York, NY |
| Elan Ezickson | Executive Officer | Cambridge, MA |
| Jeno Gyuris | Executive Officer | Houston, TX |
More